ClinicalTrials.gg
Sign In
DrugRead study by study

Olpasiran clinical trials

Also written AMG 890.

studies test it
9
open now
2
in phase 3
3
first study started
2018
ClinicalTrials.gov finds 9 studies for olpasiran. How that becomes 9 here

Every study that search finds has been read, to see whether and how it gives olpasiran. ClinicalTrials.gov counts as of Nov 11, 2026. How drug pages count

  1. 9Found by its intervention search · See all 9 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 9 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
  2. +1Give it under a name that search misses: a biosimilar’s code or a misspelling
  3. 10Give olpasiran to participants
  4. −1Observe patients on it, or give it outside a trial
  5. 9Test it: the count on this site

Get an email when these change. Save the olpasiran studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorisations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Olpasiran
8

Development codes

AMG 890
7

Studies by the year they started

9 studies that test it; most in 2022 (3)

Studies that test olpasiran, by start year
YearStudies
20181
20201
20211
20223
20241
20251
20261

By phase

A phase 1/2 study counts in both.

Phase 1
5
Phase 2
1
Phase 3
3

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Cardiovascular Diseases
4

Who runs them

Industry 9 · Other 0

Amgen (9)

Studies

Open first, then newest update. How each study uses olpasiran has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.

Testing it · 9

Tested on its own · 9 — no other medicine in its arm
Observed · 1 — patients on it are followed, or it is given outside a trial

Codes

What other systems call olpasiran · ClinicalTrials.gg INT001919

  • MeSH (NLM) C000723009olpasiranOne source ClinicalTrials.gov
  • UNII (FDA) 8M4GC1EOB4OLPASIRANOne source FDA
  • NCI Thesaurus C175176OlpasiranOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.

Start the discussion